Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
Genix Pharmaceuticals Corporation (GENPF) - Total Assets
Latest total assets as of January 2025: $56.49K USD
Based on the latest financial reports, Genix Pharmaceuticals Corporation (GENPF) holds total assets worth $56.49K USD as of January 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genix Pharmaceuticals Corporation - Total Assets Trend (2017–2024)
This chart illustrates how Genix Pharmaceuticals Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genix Pharmaceuticals Corporation - Asset Composition Analysis
Current Asset Composition (October 2024)
Genix Pharmaceuticals Corporation's total assets of $56.49K consist of 85.1% current assets and 14.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.2% |
| Accounts Receivable | $5.78K | 12.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.78K | 14.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Genix Pharmaceuticals Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genix Pharmaceuticals Corporation's current assets represent 85.1% of total assets in 2024, an increase from 73.2% in 2017.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2024, down from 25.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 14.9% of total assets.
Genix Pharmaceuticals Corporation Competitors by Total Assets
Key competitors of Genix Pharmaceuticals Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Genix Pharmaceuticals Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genix Pharmaceuticals Corporation generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genix Pharmaceuticals Corporation is currently not profitable relative to its asset base.
Genix Pharmaceuticals Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.17 | 0.03 |
| Quick Ratio | 0.04 | 0.05 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.30 Million | $ -1.20 Million | $ -238.96K |
Genix Pharmaceuticals Corporation - Advanced Valuation Insights
This section examines the relationship between Genix Pharmaceuticals Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 29.46 |
| Asset Growth Rate (YoY) | -79.6% |
| Total Assets | $45.55K |
| Market Capitalization | $1.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Genix Pharmaceuticals Corporation's assets at a significant premium ( 29.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Genix Pharmaceuticals Corporation's assets decreased by 79.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genix Pharmaceuticals Corporation (2017–2024)
The table below shows the annual total assets of Genix Pharmaceuticals Corporation from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-10-31 | $45.55K | -79.62% |
| 2023-10-31 | $223.46K | -94.75% |
| 2022-10-31 | $4.25 Million | -10.84% |
| 2021-10-31 | $4.77 Million | -10.81% |
| 2020-10-31 | $5.35 Million | +13176.71% |
| 2019-10-31 | $40.27K | -82.62% |
| 2018-10-31 | $231.72K | -41.15% |
| 2017-10-31 | $393.77K | -- |